@entity1160 ( @entity7647 ) has been shown to attenuate cytokine release from LPS-stimulated @entity1 peripheral blood mononuclear cells; however, the in vivo antiinflammatory effect of @entity7647 in polymicrobial sepsis and @entity649 is unknown. This study evaluates the effect of @entity7647 on inflammatory cytokine release and the pathways that may mediate antiinflammatory effects of @entity7647 in the lung. Either 0.75 g/kg of @entity7647 or saline placebo (SP) was administered to male @entity35 1 h after cecal ligation and puncture (CLP). NF-kappaB activation, IKBalpha degradation, phosphorylation of @entity1435 MAPK, @entity3963 , and @entity14520 expression were evaluated in lung tissue 6 h post-CLP. Lung tissue iNOS and @entity9554 , @entity310 , @entity650 , and @entity8923 cytokines were assayed. Last, lung histopathology for occurrence of @entity649 and survival were examined. @entity7647 given 1 h postsepsis led to inhibition of lung tissue NF-kappaB activation (P < 0.001 vs. SP), attenuated degradation of IKBalpha, and inhibited phosphorylation of @entity1435 MAPK, and @entity3963 , pathways critical for cytokine release. @entity7647 treatment increased @entity14520 peptide expression and significantly attenuated @entity310 and @entity650 6 h after CLP. @entity8923 was attenuated by @entity7647 at multiple time points post-CLP. Further, @entity7647 abrogated increases in lung iNOS expression and enhanced lung @entity9554 postsepsis. Finally, @entity7647 prevented the histopathologic appearance of @entity649 after sepsis and significantly improved survival. These data reveal that @entity7647 exerts an antiinflammatory effect in sepsis that may be mediated via attenuation of multiple pathways of inflammation such as NF-kappaB, @entity1435 MAPK, @entity3963 , and @entity14520 . @entity7647 also showed an inhibition of increases in iNOS expression. The antiinflammatory effect of @entity7647 was associated with attenuation of @entity649 and mortality.

GLUTAMINE PREVENTS ACTIVATION OF NF-kappaB AND STRESS KINASE PATHWAYS, ATTENUATES INFLAMMATORY CYTOKINE RELEASE, AND PREVENTS XXXX ( @entity649 ) FOLLOWING SEPSIS.

@entity1 :: ('9606', 'Species') :: ['human'] @entity650 :: ('3569', 'Gene') :: ['IL-6'] @entity9554 :: ('4846', 'Gene') :: ['eNOS'] @entity1160 :: ('CHEBI:28300', 'Chemical') :: ['Glutamine'] @entity310 :: ('7124', 'Gene') :: ['TNF-alpha'] @entity649 :: ('MESH:D012128', 'Disease') :: ['ARDS'] @entity3963 :: ('5594', 'Gene') :: ['ERK'] @entity7647 :: ('CHEBI:32668', 'Chemical') :: ['GLN'] @entity14520 :: ('1843', 'Gene') :: ['MKP-1'] @entity8923 :: ('3606', 'Gene') :: ['IL-18'] @entity1435 :: ('1432', 'Gene') :: ['p38'] @entity35 :: ('10116', 'Species') :: ['rats']
@entity649 :: (MESH:D012128,Disease) :: ['ACUTE RESPIRATORY DISTRESS SYNDROME']
